“All patients were able to undergo surgery with no delays due to neoadjuvant enfortumab vedotin–related [AEs] in this understudied population,” lead study author Thomas W. Flaig, University of Colorado Cancer Center Anschutz Medical Campus, and colleagues, emphasized in a poster of the data.